Therapeutic targets and inhibitors targeting JAK2/STAT3 signaling pathway for TNBC treatment
Potential therapeutic targets and inhibitors targeting JAK2/STAT3 signaling pathway for TNBC treatment. Occupation-driven mode: RTKs, JAK2 and STAT3-targeted inhibitors; event driven mode: small molecule compounds targeting JAK2 protein for ubiquitination degradation
Publication
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer (2024)
Lin Long, et al. Front Oncol. 2024;14(NA). Figure: F2.
| Organism |
Group |
Word |
Match |
Source |
NCBI Symbol |
NCBI ID |
| Homo sapiens |
Primates |
HOT |
HOT |
ncbigene_synonym |
ADHFE1 |
137872 |
| Homo sapiens |
Primates |
GA-A |
GAA |
ncbigene_symbol |
GAA |
2548 |
| Homo sapiens |
Primates |
JAK2 |
JAK2 |
ncbigene_symbol |
JAK2 |
3717 |
| Homo sapiens |
Primates |
DMC |
DMC |
ncbigene_synonym |
DYM |
54808 |
| Homo sapiens |
Primates |
DMC |
DMC |
ncbigene_synonym |
CXCL17 |
284340 |
| Homo sapiens |
Primates |
STAT3 |
STAT3 |
ncbigene_symbol |
STAT3 |
6774 |
| Homo sapiens |
Primates |
MSA |
MSA |
ncbigene_synonym |
TPO |
7173 |
| Word |
Match |
MeSH |
Name |
ChEBI |
| Gefitinib |
gefitinib |
|
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine |
chebi:49668 |
| N-N |
N-N |
|
L-asparaginyl-L-asparagine |
chebi:73406 |
| Ruxolitinib |
ruxolitinib |
|
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |
chebi:66919 |
| Silibinin |
silibinin |
|
(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydro-4H-chromen-4-one |
chebi:9144 |
| AG490 |
AG490 |
|
(2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide |
chebi:131968 |
| Chloroquine |
chloroquine |
|
N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine |
chebi:3638 |
| Doxazosin |
doxazosin |
|
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine |
chebi:4708 |
| Piperlongumine |
Piperlongumine |
|
|
chebi:8241 |
| Magnolol |
Magnolol |
|
|
chebi:6643 |
| JAK2 inhibitors |
JAK2 inhibitors |
|
|
chebi:76617 |
| Erlotinib |
erlotinib |
|
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine |
chebi:114785 |
| DMC |
DMC |
|
dimethyl carbonate |
chebi:36596 |
| Primaquine |
primaquine |
|
N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
chebi:8405 |
| STAT3 inhibitors |
STAT3 inhibitors |
|
|
chebi:87183 |
| Salidroside |
Salidroside |
|
|
chebi:9009 |
| Naringenin |
NARINGENIN |
|
(2S)-naringenin |
chebi:17846 |
| Hydroxyzine |
hydroxyzine |
|
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol |
chebi:5818 |
| S31-201 |
S31-201 |
|
2-hydroxy-4-{2-[(4-methylbenzene-1-sulfonyl)oxy]acetamido}benzoic acid |
chebi:91224 |
| -OH |
-OH |
|
hydroxy group |
chebi:43176 |
Disease mentions
| Word |
Match |
MeSH |
Name |
DOID |